Key Players
Competitive Landscape
The cellular repair agents market brings together beauty ingredient houses, NAD+ precursor producers and exosome developers. Croda, Lubrizol and Givaudan sell peptides and biotech actives to global brands, and Niagen Bioscience, Kingdomway and SyncoZymes supply nicotinamide riboside and NMN in bulk. Symrise is adding plant-based exosome actives, and ExoCoBio sells exosome skincare to physicians. Clinical data, proof of non-human origin and filing status will shape brand contracts through 2036.
Ingredient makers added new repair actives and cleared filing hurdles across 2025 and 2026. Givaudan introduced the Evernityl algae extract in March 2025 [17]. The FDA set aside objections to the NMN filings of SyncoZymes and Kingdomway in December 2025 [12]. Lubrizol added lip data for Argireline YOUth in February 2026 [16]. Symrise followed in April 2026 with Cellexora MD, an exosome active made from apple material [8]. Suppliers with clear origin records and supporting studies are expected to gain wider brand listings over the forecast period.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| April 2026: Symrise presented Cellexora MD, an exosome active made from upcycled apple material. | Brands want exosome claims free of human-origin material. | Plant-based exosomes are entering premium skincare. | Non-human grades can be sold in markets with strict origin rules. |
| February 2026: Lubrizol released lip data for the Argireline YOUth peptide. | Brands want repair claims beyond face serums. | Peptides are moving into lip and makeup products. | Oil-soluble peptides open colour cosmetics as a new outlet. |
| December 2025: The FDA set aside earlier objections to NMN filings by SyncoZymes and Kingdomway. | U.S. supplement brands need NMN with a clear filing status. | NAD+ precursors are returning to U.S. supplement shelves. | Filed NMN producers can secure new U.S. supplement contracts. |
| November 2025: Niagen Bioscience launched Tru Niagen Beauty. | Older shoppers link NAD+ to skin, hair and nail health. | NAD+ capsules are moving from general wellness into beauty. | Practitioner sales can pair capsules with clinic serums. |
Source: Future Market Insights, Cellular Repair Agents Market Report, 2026-2036.
Croda, Lubrizol and Givaudan all sell peptides and biotech actives, yet each differs in claim data, application labs and the share of range sold to masstige brands. Niagen Bioscience, Kingdomway and SyncoZymes compete in NAD+ precursors, a segment facing rising price pressure. Symrise and ExoCoBio both work with exosomes, though Symrise sells plant-based grades to brands and ExoCoBio sells finished skincare to clinics.
Who leads the cellular repair agents market?
Leadership in cellular repair agents is divided by ingredient type across three supplier groups. Croda has the longest peptide record, with Sederma peptides on sale since 1992 [15]. Niagen Bioscience reports the clearest NAD+ ingredient revenue, which reached USD 27.9 million in 2025 [7]. Symrise and ExoCoBio lead the most visible exosome launches. Supplier position through 2036 will follow clinical data, non-human sourcing and filing status more than portfolio size.
Which companies have documented product-level evidence?
Lubrizol backs Argireline YOUth with study data on lip roughness and wrinkles [16], and Niagen Bioscience sells a named NAD+ skin capsule, Tru Niagen Beauty [18]. Symrise and Givaudan have launched named actives with stated sources, Cellexora MD from apple material and Evernityl from algae [8] [17]. Named actives with study data are likely to gain brand listings faster than unnamed grades.
What should buyers evaluate before approving a supplier?
Brand chemists should check origin documents, stability and safety files, claim studies and, for supplements, the filing status of NMN or nicotinamide riboside. Exosome buyers also need proof of non-human origin in markets that ban human material in cosmetics [13]. Larger brands tend to favour suppliers sending batch data and regulatory support with each shipment.
How is competition expected to change through 2036?
Competition among NAD+ precursor producers is rising, as Niagen expects lower ingredient sales in 2026 with more rival producers in the market [10]. Peptide houses are set to compete on new formats, such as oil-soluble peptides for lip products. New non-human exosome actives and clinic sales routes will bring new suppliers into the market through 2036.
Representative Company Overview
| Company | Positioning | Recent Development |
|---|---|---|
| Croda | Peptide and beauty actives | February 2026: Beauty Actives sales growth of 6% reported for 2025. |
| Lubrizol | Signal peptide supplier | February 2026: lip study data released for Argireline YOUth. |
| Givaudan | Biotech and marine actives | March 2025: Evernityl algae extract launched. |
| Symrise | Exosome and longevity actives | April 2026: Cellexora MD presented at in-cosmetics Global. |
| ExoCoBio | Clinic exosome skincare | October 2025: 15 new ASCE plus products announced. |
| Niagen Bioscience | Nicotinamide riboside producer | November 2025: Tru Niagen Beauty launched. |
| Kingdomway | NMN ingredient producer | December 2025: FDA objection to the company's NMN filing set aside. |
| SyncoZymes | Enzyme-made NMN producer | December 2025: FDA objection to the company's NMN filing set aside. |
Research Methodology
Company selection covers suppliers with a launch, filing or reported result in peptides, biotech skin actives, NAD+ precursors or exosome ingredients. Primary research covers cosmetic chemists, ingredient suppliers, clinic buyers and supplement formulators. Desk research covers regulator notices, company results, ingredient filings and published studies. Market estimates are checked against supplier sales, launch activity and country adoption conditions.
